CXCL8 and COVID-19: This study analyzed interleukin‐7 (IL‐7), IL‐8, and IL‐10 promoter methylation in 145 COVID‐19 patients (91 wards, 54 intensive care units (ICUs)), excluding 12 patients receiving epigenetically active drugs.